A combination treatment of c-myc antisense DNA with all-trans-retinoic acid inhibits cell proliferation by downregulating c-myc expression in small cell lung cancer

• Published in: Antisense & nucleic acid drug development Vol. 10; no. 4; p. 243
• Main Authors: Akie, K, Dosaka-Akita, H, Murakami, A, Kawakami, Y
• Format: Journal Article
• Language: English
• Published: United States 01.08.2000
• Subjects: Antineoplastic Combined Chemotherapy Protocols - pharmacology; Apoptosis; Blotting, Northern; Blotting, Western; Carcinoma, Small Cell - drug therapy; Carcinoma, Small Cell - genetics; Carcinoma, Small Cell - metabolism; Carcinoma, Small Cell - pathology; Cell Division - drug effects; Cell Survival - drug effects; Down-Regulation; Gene Expression Regulation, Neoplastic - drug effects; Genes, myc - genetics; Humans; Oligonucleotides, Antisense - genetics; Oligonucleotides, Antisense - pharmacology; Thionucleotides - genetics; Thionucleotides - pharmacology; Tretinoin - pharmacology; Tumor Cells, Cultured
• ISSN: 1087-2906
• DOI: 10.1089/108729000421420

The dysregulation of both c-myc expression and retinoid signaling pathways commonly occurs in small cell lung cancers (SCLC), frequently accompanying tumor relapse, and contributing to the poor prognosis of patients with SCLC. In this study, we investigated whether c-myc antisense oligodeoxynucleoside phosphorothioate (OPT) covering the translational initiation site of c-myc mRNA used in combination with all-trans-retinoic acid (RA) would be more effective than either agent alone in inhibiting the growth of an SCLC cell line, NCI-H82, overexpressing c-myc with amplification of this gene, and whether this combination could be an experimental therapeutic tool against SCLC. c-myc antisense OPT decreased c-myc expression in Northern and Western blot analyses, thus inducing 40% and 20% cell growth inhibition compared with scrambled and sense OPT and with scrambled four guanosine-containing OPT (p < 0.01, and p < 0.01, respectively). All-trans-RA also inhibited cell proliferation at the rate of 40% by downregulating c-myc expression. Having obtained these results, we tested the hymothesis that c-myc antisense OPT in combination with all-trans-RA may further reduce c-myc expression and lead to improved cell growth control. This combination showed a greater inhibition of cell proliferation than either agent given alone (p < 0.01) (60% inhibition of cell growth compared with treatment of control scrambled or sense OPT alone, p < 0.01) through enhanced downregulation of c-myc expression. In conclusion, c-myc antisense DNA in combination with other modalities for c-myc downregulation may represent an attractive gene regulation-based therapy of SCLC in the future. Further efforts, however, using new oligodeoxynucleotide analogs, specific interventions for DNA delivery into cells, and more potent therapeutic agents are required to increase the potentiation of c-myc downregulation and cell growth inhibition.